Cargando…

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO. Since current antiviral therapies do not provide a curative treatment for the 296 million HBV carriers around the globe, novel strategies to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Debelec-Butuner, Bilge, Quitt, Oliver, Schreiber, Sophia, Momburg, Frank, Wisskirchen, Karin, Protzer, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670976/ https://www.ncbi.nlm.nih.gov/pubmed/36405686 http://dx.doi.org/10.3389/fimmu.2022.1029214

Ejemplares similares

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

New pharmacological strategies to fight enveloped viruses
por: Wisskirchen, Karin, et al.
Publicado: (2014)

NKX3.1 Expression Contributes to Epithelial–Mesenchymal Transition of Prostate Cancer Cells
por: Saydullaeva, Iroda, et al.
Publicado: (2023)

Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors
por: Schreiber, Sophia, et al.
Publicado: (2021)

Inflammation contributes to NKX3.1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression
por: Debelec-Butuner, Bilge, et al.
Publicado: (2015)

Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B
por: Klopp, Alexandre, et al.
Publicado: (2021)

Hepatitis-D Virus Infection Is Not Impaired by Innate Immunity but Increases Cytotoxic T-Cell Activity
por: Altstetter, Sebastian Maximilian, et al.
Publicado: (2021)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

TNFα-Mediated Loss of β-Catenin/E-Cadherin Association and Subsequent Increase in Cell Migration Is Partially Restored by NKX3.1 Expression in Prostate Cells
por: Debelec-Butuner, Bilge, et al.
Publicado: (2014)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
por: Hajduczki, Agnes, et al.
Publicado: (2020)

The redox biology network in cancer pathophysiology and therapeutics
por: Manda, Gina, et al.
Publicado: (2015)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids
por: Oner, Ezgi, et al.
Publicado: (2021)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

128 Cure of HBV infection: can APOBEC3 deaminases mediate it?
por: Protzer, Ulrike
Publicado: (2014)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment
por: Zhang, Dake, et al.
Publicado: (2012)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
por: Li, Ping, et al.
Publicado: (2021)

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
por: Kosinska, Anna D., et al.
Publicado: (2021)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Correction for Khan et al., “Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry”
por: Khan, Salar N., et al.
Publicado: (2019)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use
por: Wisskirchen, Karin, et al.
Publicado: (2017)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro
por: Xia, Yuchen, et al.
Publicado: (2017)

P73. Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes
por: Krebs, K, et al.
Publicado: (2014)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
por: Bogen, Jan P., et al.
Publicado: (2021)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy
por: Teissier, Elodie, et al.
Publicado: (2010)

A Broad-Spectrum Antiviral Peptide Blocks Infection of Viruses by Binding to Phosphatidylserine in the Viral Envelope
por: Luteijn, Rutger D., et al.
Publicado: (2020)

The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody
por: Masiero, Alessandro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3nas20i5ne0jcda8443dc3t041